Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 9792756, 13 pages
https://doi.org/10.1155/2017/9792756
Research Article

HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases

Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland

Correspondence should be addressed to Anita Chudecka-Głaz; lp.teno.atzcop@lgatina

Received 4 September 2016; Revised 17 November 2016; Accepted 1 December 2016; Published 15 January 2017

Academic Editor: Anja Hviid Simonsen

Copyright © 2017 Anita Chudecka-Głaz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Hellström, J. Raycraft, M. Hayden-Ledbetter et al., “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma,” Cancer Research, vol. 63, no. 13, pp. 3695–3700, 2003. View at Google Scholar · View at Scopus
  2. Y. Park, J.-H. Lee, D. J. Hong, E. Y. Lee, and H.-S. Kim, “Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases,” Clinical Biochemistry, vol. 44, no. 10-11, pp. 884–888, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Novotny, J. Presl, R. Kucera et al., “HE4 and ROMA index in Czech postmenopausal women,” Anticancer Research, vol. 32, no. 9, pp. 4137–4140, 2012. View at Google Scholar · View at Scopus
  4. C. Anton, F. M. Carvalho, E. I. Oliveira, G. A. R. Maciel, E. C. Baracat, and J. P. Carvalho, “A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses,” Clinics, vol. 67, no. 5, pp. 437–441, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. G. Moore, M. C. Miller, M. M. Steinhoff et al., “Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders,” American Journal of Obstetrics & Gynecology, vol. 206, no. 4, pp. 351.e1–351.e8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. R. G. Moore, D. S. McMeekin, A. K. Brown et al., “A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass,” Gynecologic Oncology, vol. 112, no. 1, pp. 40–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Molina, J. M. Escudero, J. M. Augé et al., “HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases,” Tumour Biology, vol. 32, no. 6, pp. 1087–1095, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Zheng and Y. Gao, “Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease,” International Journal of Gynecological Cancer, vol. 22, no. 6, pp. 1000–1005, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. R. G. Moore, A. K. Brown, M. C. Miller et al., “The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass,” Gynecologic Oncology, vol. 108, no. 2, pp. 402–408, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Partheen, B. Kristjansdottir, and K. Sundfeldt, “Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass,” Journal of Gynecologic Oncology, vol. 22, no. 4, pp. 244–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Fujiwara, M. Suzuki, N. Takeshima et al., “Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women,” Tumor Biology, vol. 36, no. 2, pp. 1045–1053, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. R. G. Moore, M. Jabre-Raughley, A. K. Brown et al., “Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass,” American Journal of Obstetrics and Gynecology, vol. 203, no. 3, pp. 228.e1–228.e6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. I. Braicu, R. Chekerov, R. Richter et al., “HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse,” Annals of Surgical Oncology, vol. 21, no. 3, pp. 955–962, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Bandiera, C. Romani, C. Specchia et al., “Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 12, pp. 2496–2506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. S. Buys, E. Partridge, A. Black et al., “Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial,” The Journal of the American Medical Association, vol. 305, no. 22, pp. 2295–2302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. H. D. Nelson, R. Fu, K. Goddard et al., Risk Assessment, Genetic Counselling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation, Agency for Healthcare Research and Quality, Rockville, Md, USA, 2013.
  17. A. P. M. Finch, J. Lubinski, P. Møller et al., “Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation,” Journal of Clinical Oncology, vol. 32, no. 15, pp. 1547–1553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. C. J. Reade, J. J. Riva, J. W. Busse, C. H. Goldsmith, and L. Elit, “Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis,” Gynecologic Oncology, vol. 130, no. 3, pp. 674–681, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. E. Sherman, M. Piedmonte, P. L. Mai et al., “Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group trial GOG-0199,” Journal of Clinical Oncology, vol. 32, no. 29, pp. 3275–3283, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. C. A. Shah, K. A. Lowe, P. Paley et al., “Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 5, pp. 1365–1372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. G. L. Anderson, M. McIntosh, L. Wu et al., “Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study,” Journal of the National Cancer Institute, vol. 102, no. 1, pp. 26–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Urban, J. Thorpe, B. Y. Karlan et al., “Interpretation of single and serial measures of HE4 and CA 125 in asymptomatic women at high risk for ovarian cancer,” Cancer Epidemiology, Biomarkers & Prevention, vol. 21, no. 11, pp. 2067–2094, 2012. View at Google Scholar
  23. S. Zhang, R. Royer, S. Li et al., “Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer,” Gynecologic Oncology, vol. 121, no. 2, pp. 353–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. R. I. Olivier, M. van Beurden, M. A. C. Lubsen et al., “Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up,” British Journal of Cancer, vol. 90, no. 8, pp. 1492–1497, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. D. G. R. Evans, R. Clayton, P. Donnai, A. Shenton, and F. Lalloo, “Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk,” European Journal of Human Genetics, vol. 17, no. 11, pp. 1381–1385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. I. Carcangiu, B. Peissel, B. Pasini, G. Spatti, P. Radice, and S. Monoukian, “Incidental carcinomas in prophylactic specimens in BRCA 1 and BRCA 2 germ-line mutations carriers, with emphasis on fallopian tube lesions: report of 6 cases an review of the literature,” The American Journal of Surgical Pathology, vol. 30, no. 10, pp. 1222–1230, 2006. View at Google Scholar
  27. A. Synowiec, G. Wcisło, L. Bodnar, and C. Szczylik, “Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation,” Ginekologia Polska, vol. 83, no. 1, pp. 51–56, 2012. View at Google Scholar · View at Scopus
  28. K. Haldar and R. Crawford, “Risk-reducing salpingo-oophorectomy for BRCA mutation carriers,” Maturitas, vol. 67, no. 3, p. 290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Finch, M. Beiner, J. Lubiński et al., “Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with BRCA1 or BRCA2 mutation,” The Journal of the American Medical Association, vol. 296, no. 2, pp. 185–192, 2006. View at Google Scholar
  30. G. Ruggeri, E. Bandiera, L. Zanotti et al., “HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm,” Clinica Chimica Acta, vol. 412, no. 15-16, pp. 1447–1453, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Li, H. Chen, A. Mariani et al., “HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines,” International Journal of Molecular Sciences, vol. 14, no. 3, pp. 6026–6043, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Omer, S. Genc, O. Takmaz et al., “The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients,” Tumor Biology, vol. 34, no. 5, pp. 2645–2650, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. K. Saarelainen, N. Peltonen, T. Lehtimäki, A. Perheentupa, M. H. Vuento, and J. U. Mäenpää, “Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma,” American Journal of Obstetrics and Gynecology, vol. 209, no. 2, pp. 142.e1–142.e6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. Z. Yang, C. Wei, Z. Luo, and L. Li, “Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis,” OncoTargets and Therapy, vol. 6, pp. 957–966, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. D. J. Brennan, A. Hackethal, A. M. Metcalf et al., “Serum HE4 as a prognostic marker in endometrial cancer—a population based study,” Gynecologic Oncology, vol. 132, no. 1, pp. 159–165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. A. R. Simmons, K. Baggerly, and R. C. Bast Jr., “The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas,” ONCOLOGY (United States), vol. 27, no. 6, pp. 548–556, 2013. View at Google Scholar · View at Scopus
  37. S.-W. Jiang, H. Chen, S. Dowdy et al., “HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival,” International Journal of Molecular Sciences, vol. 14, no. 11, pp. 22655–22677, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. R. G. Moore, A. K. Brown, M. C. Miller et al., “Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus,” Gynecologic Oncology, vol. 110, no. 2, pp. 196–201, 2008. View at Publisher · View at Google Scholar · View at Scopus